Proceedings of the National Academy of Sciences · 1995 · 116 citations · 20 references
Life SciencesMolecular BiologyOncologyCarcinogenesisMolecular OncologyMolecular VirologyHuman Papillomavirus InfectionOncogenic VirusesPost-translational RegulationProtein DegradationE6 ExpressionE6 OncoproteinHigh-risk Human Papillomavirus TypesLigase InhibitorsTumor Suppressor P53Ubiquitin SystemUbiquitin-mediated DegradationUbiquitin-mediated Proteolysis
The E6 protein of the high-risk human papillomaviruses inactivates the tumor suppressor protein p53 by stimulating its ubiquitinylation and subsequent degradation. Ubiquitinylation is a multistep process involving a ubiquitin-activating enzyme, one of many distinct ubiquitin-conjugating enzymes, and in certain cases, a ubiquitin ligase. In human papillomavirus-infected cells, E6 and the E6-associated protein are thought to act as a ubiquitin-protein ligase in the ubiquitinylation of p53. Here we describe the cloning of a human ubiquitin-conjugating enzyme that specifically ubiquitinylates E6-associated protein. Furthermore, we define the biochemical pathway of p53 ubiquitinylation and demonstrate that in vivo inhibition of various components in the pathway leads to an inhibition of E6-stimulated p53 degradation.
20
The Human Papilloma Virus-16 E7 Oncoprotein Is Able to Bind to the Retinoblastoma Gene Product
Nicholas J. Dyson, Peter M. Howley, Karl Münger et al. · Science · 1989 · 3.1K citations
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Elisheva Yonish-Rouach, Dalia Resnftzky, Joseph Lotem et al. · Nature · 1991 · 2.1K citations
Medicine, Hematology, Oncology +13